The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN-γ
Abstract
IL-21 is a key factor in the transition between innate and adaptive immune responses. We have used the cytokine gene therapy approach to study the antitumor responses mediated by IL-21 in the B16F1 melanoma and MethA fibrosarcoma tumor models in mice. Retrovirally transduced tumor cells secreting biologically functional IL-21 have growth patterns in vitro similar to that of control green fluorescent protein-transduced cells, but are completely rejected in vivo. We show that IL-21 activates NK and CD8+ T cells in vivo, thus mediating complete rejection of poorly immunogenic tumors. Rejection of IL-21-secreting tumors requires the presence of cognate IL-21R and does not depend on CD4+ T cell help. Interestingly, perforin, but not IFN-γ or other major Th1 and Th2 cytokines (IL-12, IL-4, or IL-10), is required for the IL-21-mediated antitumor response. Moreover, IL-21 results in 50% protection and 70% cure of nonimmunogenic tumors when given before and after tumor challenge, respectively, in C57BL/6 mice. We conclude that IL-21 immunotherapy warrants clinical evaluation as a potential treatment for cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 2×
“, with anti-cytotoxic T lymphocyte Ag, CTLA-4 Ab) (48) is required.”
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
A Critical Role for IL-21 in Regulating Immunoglobulin Production
Ozaki, K., Spolski, R., Feng, C. G., Qi, C.-F., Cheng, J., Sher, A., Morse, H. C., Liu, C., Schwartzberg, P. L., & Leonard, W. J. (2002) · Science · doi:10.1126/science.1077002 · Cited by 978
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Clinical Trials: IL-12 Deaths: Explanation and a Puzzle
Cohen, J. (1995) · Science · doi:10.1126/science.270.5238.908a · Cited by 332 · cited 1×
“The observation that tumor rejection is IFN- independent may have clinical importance, because production of IFN- during an overwhelming anti-tumor response has been accompanied by severe side effects (27, 28).”
Background
Cited by
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
Zeng, R., Spolski, R., Finkelstein, S. E., Oh, S., Kovanen, P. E., Hinrichs, C. S., Pise-Masison, C. A., Radonovich, M. F., Brady, J. N., Restifo, N. P., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041057 · Cited by 727
NK cell-based immunotherapy for malignant diseases
Cheng, M., Chen, Y., Xiao, W., Sun, R., & Tian, Z. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.10 · Cited by 631
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
“It induces a program of CD8+ T cells that leads to enhanced survival, antiviral activity, and antitumor activity (Ma et al. 2003; Wang et al. 2003; Zeng et al. 2005; Cappuccio et al. 2006; Skak et al. 2008; Spolski and Leonard 2014).”
BackgroundRobust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442
Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation
Leonard, W. J., & Spolski, R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1688 · Cited by 441
Cytokines in cancer immunity and immunotherapy
Smyth, M. J., Cretney, E., Kershaw, M. H., & Hayakawa, Y. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00199.x · Cited by 412
IL-21 Is Produced by NKT Cells and Modulates NKT Cell Activation and Cytokine Production
Coquet, J. M., Kyparissoudis, K., Pellicci, D. G., Besra, G., Berzins, S. P., Smyth, M. J., & Godfrey, D. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2827 · Cited by 364
The IL-21 receptor augments Th2 effector function and alternative macrophage activation
Pesce, J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27727 · Cited by 346
IL-21 Induces the Functional Maturation of Murine NK Cells
Brady, J., Hayakawa, Y., Smyth, M. J., & Nutt, S. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2048 · Cited by 303
Herber, D., Brown, T. P., Liang, S., Young, D. A., Collins, M., & Dunussi-Joannopoulos, K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3822 · Cited by 298
Self-citationThe IL-2 cytokine family in cancer immunotherapy
Sim, G. C., & Radvanyi, L. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.018 · Cited by 278
Young, D. A., Hegen, M., Ma, H. L. M., Whitters, M. J., Albert, L. M., Lowe, L., Senices, M., Wu, P. W., Sibley, B., Leathurby, Y., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22452 · Cited by 275
Self-citationIL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response
Li, Y., Bleakley, M., & Yee, C. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2261 · Cited by 273
Moroz, A., Eppolito, C., Li, Q., Tao, J., Clegg, C. H., & Shrikant, P. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.900 · Cited by 268
Leonard, W. J., & Wan, C.-K. (2016) · F1000Research · doi:10.12688/f1000research.7634.1 · Cited by 184
Interleukin 21: a cytokine/cytokine receptor system that has come of age
Leonard, W. J., Zeng, R., & Spolski, R. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0308149 · Cited by 122
Metadata
- Authors
- Ma, H.-L., Whitters, M. J., Konz, R. F., Senices, M., Young, D. A., Grusby, M. J., Collins, M., & Dunussi-Joannopoulos, K.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-07
- Volume
- 171
- Issue
- 2
- Pages
- 608-615
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1563636366
- Cited by
- 162
- References
- 8
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.